Literature DB >> 3395107

Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

A W Chow1, J Wong, K H Bartlett.   

Abstract

The susceptibility of 28 clinical isolates of Pseudomonas maltophilia to 16 antimicrobial agents was determined in vitro by a standard agar dilution method with inoculum sizes of 10(4) and 10(6) CFU. All isolates exhibited multiple drug resistance. Nine isolates were selected for studies of combinations of ciprofloxacin with seven antipseudomonal beta-lactams and three aminoglycosides by a checkerboard agar dilution technique. Synergistic or additive combinations of ciprofloxacin in clinically achievable concentrations were most frequent with mezlocillin (89%), followed by cefoperazone (67%), piperacillin (56%), cefsulodin (56%), and ceftazidime (33%), and were infrequent with aztreonam (11%), the aminoglycosides (0 to 14%), or imipenem (0%). Antagonism was not observed in any combination. These data suggest that combinations of ciprofloxacin with these agents may be useful for some nosocomial multiply drug-resistant P. maltophilia infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395107      PMCID: PMC172276          DOI: 10.1128/AAC.32.5.782

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia.

Authors:  P F Wheat; T G Winstanley; R C Spencer
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

2.  Minimal inhibitory concentrations of broad spectrum beta-lactam antibiotics for bacterial control strains.

Authors:  R J Fass; V L Helsel; C A Wright
Journal:  Diagn Microbiol Infect Dis       Date:  1983-03       Impact factor: 2.803

3.  Distribution in clinical material and identification of Pseudomonas maltophilia.

Authors:  B Holmes; S P Lapage; B G Easterling
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

4.  Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.

Authors:  E L Chan; R J Zabransky
Journal:  Diagn Microbiol Infect Dis       Date:  1987-02       Impact factor: 2.803

5.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

6.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia.

Authors:  V L Yu; T P Felegie; R B Yee; A W Pasculle; F H Taylor
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

8.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa.

Authors:  J J Zuravleff; V L Yu; R B Yee; M K Zaphyr; W Diven; F B Taylor
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

10.  Comparative in-vitro activity of ciprofloxacin against non-fermenters.

Authors:  M O Husson; D Izard; L Bouillet; H Leclerc
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

View more
  15 in total

1.  In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs.

Authors:  M Akova; D Gür; D M Livermore; T Kocagöz; H E Akalin
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.

Authors:  Caroline Nguyen; Alice Zhou; Ayesha Khan; Jeffrey H Miller; Pamela Yeh
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

4.  Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.

Authors:  T Lambert; M C Ploy; F Denis; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations.

Authors:  A W Chow; J Wong; K H Bartlett; S D Shafran; H G Stiver
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Authors:  J L Muñoz; M I García; S Muñoz; S Leal; M Fajardo; J A Garćia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

8.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 9.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.